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Abstract The VLDL receptor, a newly identified lipoprotein 
receptor, recognizes apoE containing lipoproteins. The human 
VLDL receptor was overexpressed in ldlA-7, a mutant Chinese 
hamster ovary cells lacking LDL receptors. Each VLDL 
obtained from a normolipidemic subject with two ~3 or £2 alleles 
similarly competed for the binding of radiolabeled rabbit ~- 
VLDL to the VLDL receptors. The anti-apoE monoclonal 
antibody 1D7, which inhibited binding of apoE3 to the LDL 
receptors, failed to compete for the binding of VLDL (apoE3 or 
apoE2) to the VLDL receptors. Results indicate that the binding 
site of apoE on the VLDL receptor may differ from its binding 
site on the LDL receptor. 
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1. Introduction 
The VLDL receptor has been identified by the cloning of a 
cDNA from a rabbit heart cDNA library [1]. The amino acid 
sequence of the VLDL receptor has a striking homology to 
the low density lipoprotein (LDL) receptor. The only marked 
structural difference between them is the number of  cysteine- 
rich repeats in the ligand binding domain. The VLDL recep- 
tor has eight repeats whereas the LDL receptor has seven. The 
VLDL receptor binds with high affinity to particles containing 
apolipoprotein E (apoE), but not LDL [1,2]. The human 
VLDL receptor has been isolated from monocytic leukemia 
cells (THP-1) and characterized; its expression is not down- 
regulated by sterols [3]. 
Type III hyperlipoproteinemia is a genetic lipid disorder 
that is characterized by the accumulation of cholesterol-rich 
chylomicron remnants and hepatic 13-VLDL. The affected pa- 
tients exhibit xanthomas, an increased propensity for prema- 
ture coronary and peripheral vascular disease, or both. Most 
patients with type III hyperlipoproteinemia are homozygous 
for a mutant form of apoE, apoE2, that differs from normal 
apoE (apoE3) by a single amino acid substitution (Cys l~s to 
Arg) [4]. I~-VLDL is rich in apoE2, which is dysfunctional 
with respect to binding to hepatic receptors leading to the 
accumulation of 13-VLDL in plasma. If  a 13-VLDL contributes 
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to atherosclerosis, the formation of foam cells must occur by a 
mechanism other than one that involves the LDL receptor. In 
the present study, we examined whether the VLDL from a 
subject homozygous for apoE2 binds the human VLDL re- 
ceptor as well as the VLDL from a subject homozygous for 
apoE3. 
2. Materials and methods 
2.1. Materials 
Monoclonal antibodies directed against apoE were generously pro- 
vided by Dr. Yves Marcel (Ottawa Heart Institute, Canada). Two 
anti-apoE antibodies were used: 1D7, an antibody that especially 
inhibits binding by apoE to the LDL receptor, and 6C5, an antibody 
that reacts with an epitope that is not involved with receptor ecogni- 
tion [5]. Antibodies were used after they were affinity purified from 
ascitic fluid. 1D7 was confirmed to inhibit binding by 
[125I]recombinant poE3 to human LDL receptor-overexpressing cells. 
2.2. Lipoprotein preparation 
VLDL (d< 1.006 g/ml) was isolated by ultracentrifugation from the 
plasma of a normolipidemic Japanese subject homozygous for the two 
e2 (Cys 15s to Arg) alleles (N.Y.) or a subject with two e3 alleles 
(K.M.) [6]. ApoE genotypes were determined by restriction isotyping 
[7]. The concentration of apoE in human VLDL was determined by 
the a single radial immunodiffusion method (APO E PLATE, Daiichi, 
Tokyo, Japan). The subject homozygous for £2 alleles was normolipi- 
demic but her plasma exhibited a broad ]3 pattern by polyacrylamide 
gel electrophoresis. Rabbit [3-VLDL (d< 1.006 g/ml) was isolated from 
the plasma of rabbits fed a diet containing 0.5% cholesterol. Bovine 
lipoprotein-deficient serum (LPDS) (d> 1.215 g/ml) was isolated from 
bovine fetal serum. Lipoproteins were labeled with 1251 by the method 
of Bolton and Hunter [8]. The final specific activity was 200-780 cpm/ 
ng protein and more than 96% of the 125I radioactivity was precipi- 
table by incubation with 10% (w/v) trichloroacetic acid. 
2.3. Isolation of transfected cells 
Plasmids encoding the human VLDL receptor (ph-VLR2) or pSV2- 
neo, which contains the neomycin resistance gene, were transfected to 
ldlA-7 cells (mutant Chinese hamster ovary cells that lack LDL re- 
ceptors) which was kindly provided by Dr. Monty Krieger (Depart- 
ment of Biology, Massachusetts Institute of Technology, Cambridge, 
MA) using lipofectin as described previously [1-3,9,12]. Positive cell 
clones for the human VLDL receptor were designated VLDL-R cells. 
A transfectant with only pSV2-neo was used for control cells (Neo). 
2.4. Cell culture and ligand binding assays 
For experiments designed to assay the ligand binding activity of the 
transfectants, 125I-labeled lipoproteins were added to the cells in 
Ham's F-12 medium supplemented with 5% LPDS. After 4 h at 
37°C, the cell association (binding and internalization) of 
[125I]lipoproteins was measured as described by Goldstein and Brown 
[10]. Cellular protein was measured according to the method of Lowry 
et al. [11]. To exclude the effect of LRP (LDL receptor-related pro- 
tein), specific activity was determined by subtracting the radioactivity 
associated with Neo cells from that associated with VLDL-R cells 
[12]. All binding assays were performed in triplicate. 
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2.5. Solubilization of cell membrane and ligand blotting assay 
Membrane fractions of transfected cells were prepared by the meth- 
od of Hofmann et al. [13]. Ligand blotting was performed with 1251- 
labeled lipoproteins as described before [12]. 
3. Results 
kDa 
3.1. Binding of VLDL of apoE3/3 and apoE2/2 to the VLDL 
receptor 
Human fasted [12~I]VLDL from normolipidemic subjects 
has been shown to bind the VLDL receptor with lower affinity 
compared with 13-VLDL from cholesterol-fed rabbits [12]. 
Competitive binding assays in cell culture were performed 
using [125I]rabbit 13-VLDL instead of human VLDL. The 
VLDL of apoE3/3 and the VLDL of apoE2/2 competed for 
the binding of radiolabeled rabbit [3-VLDL to the VLDL 
receptor with similar affinities (Fig. 1). Repeated experiments 
(n=3) could not distinguish the ability of the two kinds of 
VLDL to compete with the binding of [125I]13-VLDL. 
A ligand blot assay was performed to ensure whether the 
VLDL binds to the VLDL receptor (Fig. 2). Ligand blot was 
employed because this method has higher sensitivity and spe- 
cificity than the cell culture binding assay. Both the VLDL of 
apoE3/3 and the VLDL of apoE2/2 certainly bound to the 
VLDL receptor. Additional bands such as LRP were not visi- 
ble. Although the intensity of the band was greater in the 
apoE2/2 lane in this experiment, his was not always shown 
in the repeated experiments (Fig. 3). 
3.2. Effect of anti-apoE antibodies 
The effect of 1D7, an antibody that especially inhibits bind- 
ing by apoE to the LDL receptor, and 6C5, an antibody that 
reacts with an epitope that is not involved with receptor e- 
cognition, on the binding of [125I]VLDL of apoE3/3 to the 
VLDL receptor was examined by ligand blot assay and cell 
culture binding assay. In the case of ligand blot assay (Fig. 3), 
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Fig. 1. Ability of the VLDL from a normolipidemic subject with 
two e3 alleles and a normolipidemic subject with two E2 alleles to 
compete with rabbit [125I]I3-VLDL for binding to VLDL receptors. 
Cell association (binding and internalization) of [125I]lipoproteins as 
a function of apoE concentration. Specific activity is shown, calcu- 
lated by subtracting the radioactivity associated with Neo cells from 
that associated with VLDL-R cells to exclude the effect of LRP. 
The 100% control value with no added human VLDL was 73.9 ng 
of [125I][~-VLDL/mg of cellular protein. Each point is the average of 
triplicate dishes. Representative experiment. 
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Fig. 2. Binding of human [125I]VLDL of apoE3/3 and apoE2/2 to 
cell membrane fractions of Neo and VLDL-R cells. Membrane frac- 
tions from each transfectant were solubilized, fractionated on 7.5% 
SDS-polyacrylamide g ls under nonreducing conditions, and trans- 
ferred to a nitrocellulose filter. The filter was incubated with 
[125I]VLDL of apoE3/3 (2.2 Ixg of apoE/ml, 217 cpm/ng protein) (1) 
or [125I]VLDL of apoE2/2 (2.2 gg of apoE/ml, 220 cpm/ng protein) 
(2) in binding buffer containing 2 mM CaC12. A total of 7 gg of 
protein was loaded onto each lane. The filter was exposed to Kodak 
XAR5 film for 72 h at -70°C. Representative experiment. 
20 gg/ml of 1D7 or 6C5 antibodies did not affect the band 
corresponding to the VLDL receptor blotted by [lZSI]VLDL 
of apoE2/2 or [125I]VLDL of apoE3/3. In the cell culture 
binding assay (Fig. 4), neither 1D7 nor 6C5, in doses ranging 
from 6.25 gg/ml to 50 gg/ml, inhibited the binding of 
[125I]VLDL of apoE3 to the VLDL receptor. In this range, 
1D7 antibody inhibited the binding of recombinant 
[125I]apoE3 emulsified with dimyristoyl phosphatidylcholine 
to the human LDL receptor-overexpressing cells in a concen- 
tration-dependent manner (data not shown). 
4. Discuss ion 
The VLDL obtained from a normolipidemic subject with 
two e2 alleles, as well as the VLDL obtained from a normo- 
lipidemic subject with two e3 alleles bound to VLDL recep- 
tors with comparable affinities. Also, the anti-apoE monoclo- 
nal antibody 1D7, which inhibits binding of apoE3 to LDL 
receptors, failed to compete with the binding of either apoE3/ 
3 VLDL or apoE2/2 VLDL to the VLDL receptor. These 
results raise the possibility that the region of the apoE mole- 
cule that binds to the VLDL receptor is not identical to the 
region that binds to the LDL receptor. ApoE2 has been 
shown to posses only 0.5 1.0% of the normal apoE3 binding 
activity toward the LDL receptor [14,15]. The region of apoE 
responsible for binding to the LDL receptor has been loca- 
lized to amino acids 136-150 [5,16]. Although a striking fea- 
ture of the VLDL receptor is its structural similarity to the 
LDL receptor, only apoE containing lipoproteins, not apoB 
containing LDL, bind to it. A key structural difference be- 
tween the two receptors is the number of cysteine-rich repeat 
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sequences at the N-terminus. The VLDL receptor contains an 
8-fold repeat whereas the LDL receptor consists of a 7-fold 
repeat. The LDL binding function of the LDL receptor e- 
quires contributions from repeats 3-7, whereas [3-VLDL bind- 
ing was insensitive to the loss of any single repeat, except for 
repeat 5 [17,18]. The addition of one more ligand binding 
repeat in the VLDL receptor may inhibit the binding of 
LDL to this receptor and makes the VLDL receptor less dis- 
criminatory against molecules other than apoE3 such as 
apoE2. A similar relaxed specificity toward different isoforms 
of human apoE has been observed in a 95-kDa oocyte-specific 
receptor to vitellogenin (VTG), which also binds human and 
rabbit apoE with high affinity [19]. This receptor was recently 
identified as a VLDL receptor in chicken oocyte, and termed 
the VLDL/VTG receptor [20]. 
The binding site of human apoE to the LDL receptor con- 
tains clusters of positively charged and hydrophobic residues 
(residues 143-150, Lys-Leu-Arg-Lys-Arg-Leu-Leu-Arg). All 
of these residues lie on helix 4, one of five helices located in 
the N-terminal domain of apoE [21]. The regions of human 
apoB-100 that contain such clusters have been implicated in 
binding to the LDL receptor (residues 3359-3368, Arg-Leu- 
Thr-Arg-Lys-Arg-Gly-Leu-Lys-Leu) [22,23]. Furthermore it 
has been shown that two such clusters of VTG, residues 
493498 (Leu-Lys-Arg-Ile-Leu-Lys) and residues 1079-1084 
(Lys-Leu-Lys-Arg-Ile-Leu), mediate binding to the VLDL/ 
VTG receptor. It is conceivable that the binding site of 
apoE to the VLDL receptor contains uch clusters [24]. The 
N-terminal portion of helix 4 contains uch clusters, including 
Arg TM, Arg 136, His 140, Arg 142, Lys143, Arg 145, Lys 146, Arg 147, 
and Arg 15°. Because the 1D7 epitope is shown to be most 
likely localized in the immediate vicinity of residues 145 and 
146 [5], the binding site of human apoE to the VLDL receptor 
might be residues 132-144. Direct binding experiments using 
synthetic peptides of apoE are planned to determine the bind- 
ing site of apoE to the VLDL receptor. Very recently it has 
been shown that the VLDL receptor binds to and mediates 
the catabolism of LPL and urokinase complexed with plasmi- 
nogen activator-inhibitor type I [25]. It raises the possibility 
that LPL, which would be present in the prepared VLDL 
fraction, may participate in the binding of VLDL to the 
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Fig. 3. The effect of apoE monoclonal antibodies on the binding of 
[12sI]VLDL to cell membrane fractions of VLDL-R cells. Nitrocellu- 
lose filters containing membrane fractions of VLDL-R cells were 
prepared as described in the legend to Fig. 2. Replicate filters were 
blotted in the presence of [125I]VLDL of apoE3/3 (2.5 ktg of apoE/ 
ml, 859 cpm/ng protein) (top) or [12~I]VLDL of apoE2/2 (2.5 ~tg of 
apoE/ml, 654 cpm/ng protein) (bottom). [125I]VLDL was preincu- 
bated with 20 ~g/ml of 1D7 (+lD7) or 6C5 (+6C5) for 1 h at room 
temperture and then used for blotting. 
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Fig. 4. The effect of apoE monoclonal ntibodies on the binding of 
[12sI]VLDL to VLDL-R cells. [I~I]VLDL of apoE3/3 (780 cpm/ng 
of protein) was preincubated with the indicated concentrations of 
each antibody for 1 h at room temperture and then added to the 
wells. Final concentration of [12~I]VLDL was 10 ktg protein/ml. 
Then the cells were incubated for 4 h at 37°C, and the amount of 
[125I]VLDL that bound to the cells was determined. The specific ac- 
tivity is shown, calculated by subtracting the radioactivity associated 
with Neo cells from that associated with VLDL-R cells to exclude 
the effect of LRP. The 100% control value with no added antibodies 
was 68 ng of [I~SI]VLDL/mg of cellular protein. Each point is the 
average of triplicate dishes. Representative experiment. 
VLDL receptor. But it seems to be unlikely because plasma 
LPL concentrations of subjects K.M. (apoE3/3) and N.Y. 
(apoE2/2) without heparin infusion were not detectable 
(<25 ng/ml) by enzyme immunoassay (MARKIT-F LPL, 
Dainippon, Tokyo, Japan). 
The scavenger receptor LRP and the VLDL receptor are 
not down-regulated by sterols and are candidate receptors for 
foam cell formation. Human VLDL obtained from fasted 
subjects has a significantly reduced ability to bind to the 
VLDL receptor compared with rabbit 13-VLDL. But apoE 
and LPL, which are secreted from macrophages, enhanced 
the binding of human VLDL to the VLDL receptor [12], 
supporting the hypothesis that the VLDL receptor pathway 
may contribute to foam cell formation. 
VLDL from patients homozygous for apoE2 or apoE3 
bound the human VLDL receptor identically. It is possible 
that the VLDL receptor may contribute to atherosclerosis 
thorough foam cell formation, especially in patients with 
type III hyperlipoproteinemia. 
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